ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance

During the past decade, more than 10 targetable oncogenic driver genes have been validated in non-small cell lung cancer (NSCLC). Anaplastic lymphoma kinase (ALK) and ROS1 kinase are two new driver genes implicated in ALK- and ROS1-rearranged NSCLC. Inhibition of ALK and ROS1 by crizotinib has been...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncotarget
Main Authors: Ye, Mingxiang, Zhang, Xinxin, Li, Nan, Zhang, Yong, Jing, Pengyu, Chang, Ning, Wu, Jianxiong, Ren, Xinling, Zhang, Jian
Format: Artigo
Sprog:Inglês
Udgivet: Impact Journals LLC 2016
Fag:
Review
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4914285/
https://ncbi.nlm.nih.gov/pubmed/26802023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6935
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker